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Abstract
Objectives: To	compare	clinical	performance	of	a	novel	resorbable	non-cross-linked	
collagen	membrane	(CXP)	with	a	reference	membrane	(non-cross-linked	resorbable	
membrane;	BG)	for	simultaneous	implant	placement	and	guided	bone	regeneration	
(GBR)	at	dehisced	single	implant	sites.
Materials and methods: Preliminary	data	from	this	randomized	controlled	trial	were	
reported	previously;	this	is	the	12-month	report.	The	primary	outcome	measure	was	
defected	height	at	6	months	post-GBR.	Secondary	outcomes	 included	 implant	cu-
mulative	survival	rate	(CSR)	and	success	rate	since	placement;	bone	level	changes,	
pink	esthetic	score	(PES),	and	patient	satisfaction	since	definitive	prosthesis	delivery;	
patient	quality	of	life	since	pretreatment;	and	the	1-year	bleeding	index.	Non-para-
metric	statistical	analyses	were	performed.
Results: Among	patients,	24	were	treated	with	CXP	and	25	with	BG.	The	1-year	im-
plant	CSR	and	success	rate	were	100%	(n	=	42).	Bone	level	change	between	definitive	
prosthetic	delivery	and	1	year	was	not	significantly	different	between	the	CXP	and	
BG	groups	(BG	+	0.42	mm,	CXP	+	0.01	mm).	The	PES	increased	from	7.55	to	8.10	
for	the	CXP	group	and	from	6.48	to	7.48	for	the	BG	group;	1-year	bleeding	indices	
were	0	(16	CXP,	18	BG)	and	1	(4	CXP,	2	BG).	Patient	quality	of	life	changed	from	an	
OHIP-14	 score	of	6.5	at	pretreatment	 to	1.9	at	1	year.	Overall	 satisfaction	 (visual	
analogue	score)	with	function	and	esthetics	was	9.9	and	9.7,	respectively.	Inter-group	
differences	were	not	significant	for	assessed	outcomes.	No	device-related	adverse	
events	were	reported.
Conclusions: The	use	of	CXP	and	BG	for	simultaneous	implant	placement	and	GBR	
at	dehisced	 implant	 sites	 similarly	 reduced	defect	height	 and	 improved	 secondary	
measures,	indicating	non-inferiority.
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1  | INTRODUC TION
Since	 the	 introduction	 of	 restoratively	 driven	 implant	 placement,	
in	 which	 prosthetic	 devices	 are	 designed	 based	 on	 the	 exact	 im-
plant	 location	 (Albrektsson,	Berglundh,	&	 Lindhe,	 2003;	Garber	&	
Belser,	 1995),	 bone	 augmentation	has	 played	 an	 important	 role	 in	
dental	implant	surgeries	and	often	is	one	of	the	key	factors	contrib-
uting	to	a	successful	implant	treatment.	In	the	12	months	following	
tooth	extraction,	the	alveolar	ridge	can	resorb	dramatically,	reduc-
ing	its	width	by	approximately	50%	(Schropp,	Wenzel,	Kostopoulos,	
&	 Karring,	 2003),	 with	 most	 of	 the	 resorption	 occurring	 within	
3	months	post-implantation	 (Araújo,	Wennström,	&	Lindhe,	2006).	
To	 achieve	 successful	 esthetic	 and	 functional	 results,	 it	 is	 often	
necessary	 to	preemptively	correct	 for	bone	resorption	using	bone	
augmentation,	 especially	 for	 implants	 placed	 in	 the	 esthetic	 zone	
(Khzam	et	al.,	2015;	Nisand,	Picard,	&	Rocchietta,	2015).
Many	high-quality	 studies	 investigating	guided	bone	 regenera-
tion	(GBR)	to	augment	the	lateral	alveolar	ridge	have	shown	repro-
ducible	 results	 and	high	 implant	 survival	 rates	 long	 term	 (Aghaloo	
&	 Moy,	 2007;	 Sanz-Sanchez,	 Ortiz-Vigon,	 Sanz-Martin,	 Figuero,	
&	 Sanz,	 2015).	 Studies	 have	 investigated	 the	 combination	 of	GBR	
with	 simultaneous	 and	 subsequent	 implant	 placement.	 The	 two	
approaches	achieved	similar	 survival	 rates,	 indicating	 they	are	 rel-
atively	equivalent	 (Sanz-Sanchez	et	al.,	2015).	 Importantly,	 implant	
placement	 in	augmented	or	pristine	bone	results	 in	similar	 implant	
survival	rates,	demonstrating	the	predictability	and	efficacy	of	GBR	
(Donos,	Mardas,	&	Chadha,	2008).
Lateral	ridge	augmentation	via	GBR	with	the	combination	of	a	re-
sorbable	collagen	membrane	and	particulate	graft	materials	is	a	fre-
quently	reported	technique	in	the	literature,	especially	when	treating	
dehiscence	defects	(Schwarz,	Sahm,	&	Becker,	2012;	Wang,	Misch,	
&	Neiva,	2004).	Application	of	this	technique	produces	equally	high	
long-term	implant	survival	rates	whether	used	subsequently	to	or	si-
multaneously	with	implant	placement	(Wessing,	Lettner,	&	Zechner,	
2018).	 Therefore,	 a	 simultaneous	 approach	 is	 indicated	whenever	
possible,	as	it	reduces	the	number	of	surgeries,	which	lowers	morbid-
ity,	reduces	treatment	time,	and	increases	patient	comfort	(Wessing	
et	al.,	2017).	Use	of	non-cross-linked	membranes	is	recommended	in	
this	approach,	because	cross-linked	membranes	are	associated	with	
approximately	30%	higher	membrane	exposure	rate	(Wessing	et	al.,	
2018),	which	can	negatively	affect	GBR	around	dental	implants	and	
often	 reduce	bone	 regeneration	 (Garcia	 et	 al.,	 2018).	Creos	 xeno-
protect	(CXP,	Nobel	Biocare	AB,	Göteborg,	Sweden)	is	a	resorbable	
collagen	membrane	made	from	purified	porcine	collagen	and	elastin	
that	has	not	been	chemically	cross-linked.	CXP	does	not	 require	a	
reentry	procedure	to	remove	the	membrane	and	has	demonstrated	
a	much	lower	wound	dehiscence	rate	when	used	for	GBR.
The	 aim	 of	 this	 randomized	 controlled	 study	 was	 to	 evaluate	
bone	 formation	and	 soft	 tissue	healing	 after	6	months	 in	patients	
with	dehiscence	defects.	The	trial	compared	two	different	resorb-
able	non-cross-linked	collagen	membranes	as	part	of	the	GBR	proce-
dure.	The	interim	results	of	this	study	have	been	previously	reported	
and	showed	 that	 the	use	of	both	membranes	was	associated	with	
low	membrane	exposure	rates	and	significant	bone	gain	6	months	
post-augmentation	 (Wessing	 et	 al.,	 2017).	 In	 this	 manuscript,	 we	
present	the	functional	and	esthetic	outcomes	of	the	implant–pros-
thetic	restoration,	changes	in	quality	of	life,	bone	level	changes,	and	
soft	tissue	evaluation	at	the	time	of	prosthetic	delivery	and	at	1-year	
recall.	We	hypothesized	that	GBR	using	CXP	would	not	be	inferior	to	
that	using	Bio-Gide	(BG,	Geistlich).
2  | MATERIAL S AND METHODS
2.1 | Ethical considerations
This	multicenter	clinical	study,	involving	seven	university	clinics	and	
private	 practices	 in	 Europe,	 including	 Austria,	 Germany,	 Hungary,	
Italy,	and	Spain,	was	conducted	according	to	 the	ethical	principles	
set	 by	 the	 Declaration	 of	 Helsinki	 and	 is	 reported	 following	 the	
Consort	2010	guidelines	for	reporting	parallel	group	randomized	tri-
als	(Schulz,	Altman,	&	Moher,	2010).	(See	supplementary	material)
Ethical	 approvals	 were	 obtained	 at	 each	 center	 involved	 in	
the	study.	Approval	numbers	 for	were	as	 follows:	Protocol	54129,	
approval	 526	 (Verona);	 48363-004/2013	 (Budapest);	 2013385	
(Aachen);	1724/2013	(Vienna);	837.518.13	(Mainz);	14/242	(Madrid);	
and	2172/CE	(Sassari).	All	clinicians	that	took	part	in	the	study	were	
experienced	surgeons	who	received	training	on	the	study	protocol	
prior	to	the	start	of	the	trial.
2.2 | Study design and eligibility criteria for 
participants
Study	 design	 and	 participant	 eligibility	 criteria	were	 as	 previously	
described	 (Wessing	 et	 al.,	 2017).	 Briefly,	 this	 randomized	 clinical	
trial	was	designed	to	evaluate	bone	formation	and	soft	tissue	heal-
ing	with	GBR	at	single	implant	sites	with	dehiscence	defects	treated	
using	CXP	(Nobel	Biocare	AB)	or	BG	(Geistlich).
The	 primary	 inclusion	 criteria	 were	 as	 follows:	 (a)	 written	 in-
formed	consent;	(b)	≥18	years	of	age	and	ceased	growth;	(c)	physical	
and	mental	capability	to	participate	throughout	the	5-year	follow-up	
period;	 (d)	willingness	 and	 ability	 to	 comply	with	 all	 study-related	
procedures;	 (e)	need	of	a	single-unit	 implant	restoration	 in	the	an-
terior	and	premolar	areas	of	maxilla	or	mandible	with	GBR	of	bony	
defects,	defined	as	a	height	of	≥3	mm	and	≤7	mm	if	horizontal	width	
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was	>2	mm,	or	a	height	of	>7	mm	and	≤10	mm	if	the	width	was	≤2	mm;	
(f)	American	Society	of	Anesthesiologists	score	of	I	or	II;	(g)	implant	
site	free	of	infection	and	extraction	remnants;	(h)	full-mouth	gingival	
index	lower	than	25%,	a	full-mouth	bleeding	score	lower	than	25%,	
and	a	full-mouth	plaque	score	≤25%;	(i)	favorable	and	stable	occlusal	
relationship	and	natural	tooth	roots	adjacent	to	the	implant	site;	and	
(j)	ability	to	undergo	a	two-stage	surgical	procedure.
Patients	were	excluded	due	to	the	following:	 (a)	previous	bone	
augmentation	at	the	implant	site;	(b)	tooth	extraction	at	the	implan-
tation	site	performed	within	3	months	of	implant	placement	surgery;	
(c)	 acute,	untreated	periodontitis;	 (d)	health	condition	 that	did	not	
permit	surgical	 treatment;	 (e)	any	disorders	 in	the	planned	 implant	
area,	such	as	previous	tumors,	chronic	bone	disease,	or	previous	ir-
radiation;	(f)	an	infection	in	the	planned	implantation	site	or	adjacent	
tissue;	(g)	ongoing	treatment	with	an	interfering	medication,	such	as	
steroid	therapy	or	bisphosphonates;	(h)	a	history	of	past	or	ongoing	
alcohol	or	substance	abuse;	(i)	heavy	smoking	(>10	cigarettes/day);	(j)	
uncontrolled	diabetes;	(k)	severe	bruxism	or	other	destructive	hab-
its;	and	(l)	pregnancy	or	breastfeeding	at	the	time	of	collagen	mem-
brane	insertion.
At	 the	 time	 of	 surgery,	 patient's	 eligibility	 was	 reassessed.	
Patients	were	included	if	they	(a)	had	sufficient	bone	volume	at	the	
implant	 site	 to	place	a	10-mm-long	 tapered	 implant,	 (b)	 had	 initial	
implant	 stability	 as	 assessed	by	hand	 testing,	 and	 (c)	 had	a	defect	
size	 that	would	classify	 for	a	GBR	procedure	 (defects	with	one	or	
two	walls	missing,	defect	height	(DH)	measured	from	the	top	of	the	
implant	 shoulder	 to	 the	 first	 bone-to-implant	 contact	 (Jung,	Halg,	
Thoma,	&	Hammerle,	2009)	of	3	mm	up	to	7	mm;	larger	defects	up	
to	10	mm	were	eligible	if	the	defect	width	did	not	exceed	2	mm).	All	
defect	measurements	were	 performed	with	 a	UNC15	periodontal	
probe.
Allocation	 concealment	was	 performed	 through	 the	 electronic	
data	 capture	 system	 (EDC,	 Viedoc©;	 Pharma	 Consulting	 Group,	
Uppsala,	Sweden).	Allocation	of	the	patients	to	the	different	treat-
ments	groups	was	performed	at	the	time	of	surgery	and	was	based	
on	a	built-in	randomization	list	supplied	by	the	EDC	system.
The	patients	and	the	evaluators	were	blinded	to	the	treatment.	
If	patients	had	two	or	more	sites	requiring	single-unit	 implant	res-
torations	with	bone	augmentation,	only	one	site	was	randomly	 in-
cluded	in	the	study.	The	other	site	was	treated	with	standard	care.
After	implant	placement	(NobelReplace	CC;	Nobel	Biocare	AB),	
the	 osseous	 defect	 of	 the	 eligible	 site	was	 characterized	 as	 de-
scribed	by	Jung	et	al.,	2009.	Decortication	holes	were	made	in	the	
planned	bone	augmentation	area	to	draw	blood	from	the	cancel-
lous	bone	into	the	graft	site.	Autologous	bone	chips	collected	from	
the	retromolar	area	were	then	placed	on	the	surface	of	the	dental	
implant,	 and	 anorganic	 bovine	 bone	mineral	 (Bio-Oss,	 Geistlich)	
was	placed	on	top	of	the	bone	chips	for	slower	resorption	accord-
ing	to	the	previously	described	sandwich	technique	(Wang	et	al.,	
2004).	After	placement	of	the	particulate	bone	graft,	the	collagen	
membrane	 (either	CXP	 or	 BG)	was	 trimmed,	 positioned,	 and	 re-
hydrated	with	 sterile	 saline	 solution.	 In	 all	 cases,	 the	membrane	
was	fixed	using	either	periosteal	vertical	mattress	sutures	(Urban,	
Lozada,	Wessing,	Suarez-Lopez	Del	Amo,	&	Wang,	2016)	or	tita-
nium	cortical	bone	pins.	Both	 fixation	methods	were	used	 to	 in-
clude	 clinicians	 who	 preferred	 not	 to	 use	 pins.	 The	 numbers	 of	
patient	who	had	their	membranes	fixed	with	sutures	and	pins	were	
approximately	 equal	 between	 groups	 (pins,	 13	 CXP	 and	 12	 BG;	
sutures,	11	CXP	and	13	BG).
Provisional	prosthetic	installation	was	planned	to	be	performed	
within	 4	weeks	 after	 the	 reentry	 but	 left	 at	 the	 discretion	 of	 the	
investigator.	 Titanium	 and/or	 zirconia	 temporary	 abutments	 were	
used	for	the	fabrication	of	temporary	screw-retained	or	cement-re-
tained	restorations.	Definitive	prosthetic	installation	was	planned	to	
be	made	within	3	months	after	reentry.	Patients	received	Esthetic	
abutments,	Procera	Esthetic	 abutments,	 and	Procera	Full	Contour	
Zirconia	abutments	(all	Nobel	Biocare	AB).	For	the	final	restoration,	
both	cement	retention	and	screw	retention	were	allowed.
2.3 | Outcome measures
The	 primary	 outcome	measure	 was	 defined	 as	 the	 DH	measured	
with	the	UNC	15	periodontal	probe	6	months	after	the	augmenta-
tion	procedure	and	was	reported	previously	(Wessing	et	al.,	2017).	
The	secondary	outcome	measures	evaluated	 in	 this	 report	 include	
implant	survival	and	success	rates,	peri-implant	bone	response,	soft	
tissue	 health,	 patient	 quality	 of	 life,	 and	 esthetic	 and	 functional	
satisfaction.
A	 “surviving	 implant”	was	defined	as	an	 implant	 that	 remained	
in	 the	 jaw	 and	was	 stable,	 and	when	 the	 subject's	 treatment	was	
functionally	successful	even	though	all	the	individual	success	criteria	
were	not	necessarily	fulfilled.	A	“failed	 implant”	was	defined	as	an	
implant	that	was	removed,	fractured	beyond	repair,	or	could	not	be	
classified	as	a	surviving	implant.
The	implant	success	criteria	used	in	this	investigation	are	a	mod-
ification	of	the	success	criteria	introduced	by	van	Steenberghe	(van	
Steenberghe,	1997)	and	define	a	successful	 implant	as	one	that	(a)	
does	not	cause	allergic,	toxic,	or	gross	infectious	reactions	either	lo-
cally	or	systemically,	(b)	offers	anchorage	to	a	functional	prosthesis,	
(c)	does	not	show	any	signs	of	fracture	or	bending,	(d)	does	not	show	
any	mobility	when	individually	tested	by	tapping	or	rocking	with	a	
hand	instrument,	and	(e)	does	not	show	any	signs	of	radiolucency	on	
an	intraoral	radiograph	using	a	paralleling	technique	strictly	perpen-
dicular	to	the	implant–bone	interface.
Marginal	bone	levels	(MBLs)	were	evaluated	using	periapical	ra-
diographs.	Radiographic	examination	was	performed	using	a	 stan-
dardized	 long-cone	 parallel	 technique	 with	 a	 custom-made	 bite	
block	and	a	reference	metal	ball.	Only	images	including	the	implant	
platform	and	clearly	visible	threads	were	used	for	analysis.	 Images	
were	imported	into	Adobe	Illustrator	for	analysis.	Bone	height	was	
measured	 using	 Adobe	 Illustrator	 by	 an	 independent	 radiologist	
(University	 of	 Gothenburg,	 Gothenburg,	 Sweden)	 as	 the	 distance	
between	the	most	apical	bone	level	to	the	implant–abutment	junc-
tion.	Distance	was	calibrated	to	the	implant	diameter,	and	measure-
ments	were	accurate	to	0.1	mm.	MBLs	are	presented	as	averages,	
(mesial	+	distal)/2.	Negative	numbers	indicate	bone	levels	below	the	
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reference	 point,	 and	 positive	 numbers	 indicate	 bone	 levels	 above	
the	reference	point.
Bone	 level	 changes	were	 calculated	 for	 each	 side	 of	 the	 im-
plant	 (mesial	 and	 distal)	 separately.	 The	 average	 of	 mesial	 and	
distal	 changes	 is	 then	 calculated	 for	 each	 implant	 site	 (paired	 for	
each	side	between	two	different	points).	The	radiograph	collected	
at	 definitive	 prosthetic	 delivery	 was	 designated	 as	 the	 baseline.	
Negative	numbers	 indicate	bone	 loss,	 and	positive	numbers	 indi-
cate	bone	gain.
Soft	tissue	health	was	evaluated	using	PES	and	mBI	parameters.	
The	PES	was	assessed	according	to	Fürhauser	et	al.	(Furhauser	et	al.,	
2005)	by	an	external	blinded	evaluator	(Vienna	Medical	University,	
Austria)	and	based	on	intraoral	pictures	taken	perpendicular	to	the	
definitive	restoration.	The	bleeding	tendency	was	assessed	using	a	
modified	Sulcus	Bleeding	 Index	 (mBI)	 according	 to	Mombelli	 et	 al.	
(Mombelli,	van	Oosten,	Schurch,	&	Land,	1987).
Patient	quality	of	life	was	evaluated	using	the	Oral	Health	Impact	
Profile	 (OHIP-14;	 Brennan	 &	 Spencer,	 2004).	 The	OHIP-14	 ques-
tionnaires	were	made	available	in	the	respective	local	languages	and	
validated	 translations	 and	 rated	 the	 prevalence	 of	 patients'	 func-
tional	 limitations;	physical	pain;	psychological	discomfort;	physical,	
psychological,	 and	 social	 disability;	 and	 handicap.	 The	 responses	
to	the	 individual	questions	were	scored	on	a	0–4	scale	as	 follows:	
never	=	0,	hardly	ever	=	1,	occasionally	=	2,	fairly	often	=	3,	and	very	
often	=	4.
Patient	 satisfaction	 with	 function	 and	 esthetics	 was	 assessed	
using	a	visual	analogue	scale	with	ratings	1–10,	where	10	=	fully	sat-
isfied	 and	1	=	not	 satisfied	 according	 to	Belser	 et	 al.	 (Belser	 et	 al.,	
2009).
Prior	 to	 the	 start	 of	 the	 study,	 all	 participating	 clinicians	were	
trained	 in	 the	 surgical	 protocols	 and	 collection	 of	 outcome	 mea-
sures.	This	training	included	hands-on	sessions	using	models	repre-
senting	the	study	indications.
The	 time	 schedule	 for	 parameter	 assessment	 described	 in	 this	
report	is	shown	in	Table	1.
2.4 | Statistical methods
Power	analyses	to	determine	the	number	of	participants	to	recruit	
were	described	previously	(Wessing	et	al.,	2017).	Briefly,	the	study	
design	aimed	to	test	non-inferiority	(margin	of	inferiority	defined	as	
1	mm	with	a	standard	deviation	of	0.94	mm).	Assuming	25%	subject	
withdrawal,	20	participants	per	arm	were	needed.	All	available	data	
after	reentry	surgery	and	until	the	1-year	follow-up	were	included	in	
the	data	analysis.	Missing	data	were	not	imputed	and	not	included	
to	the	statistical	evaluation.	The	CSR	and	implant	success	rate	were	
calculated	based	on	a	life-table	analysis.	The	distribution	of	continu-
ous	variables	was	given	as	mean,	 standard	deviation	 (SD),	median,	
minimum,	and	maximum,	and	for	categorical	variables	as	frequency	
and	percentage.	The	mBI	was	analyzed	as	an	ordinal	categorical	vari-
able	by	aggregate	using	the	most	severe	bleeding	for	each	implant.	
For	 comparison	 between	 the	 two	 randomized	 groups,	 CXP	 and	
BG,	 the	Mann–Whitney	U	 test	was	used	 for	 continuous	variables,	
Mantel–Haenszel	chi-square	test	 for	ordered	categorical	variables,	
and	Fisher's	exact	 test	 for	dichotomous	variables.	For	comparison	
of	 change	within	 the	 groups,	Wilcoxon	 signed-rank	 test	was	used	
for	continuous	variables	and	McNemar's	test	for	ordered	categorical	
variables	and	dichotomous	variables.	All	significance	tests	were	two-
sided	and	conducted	at	significance	level	of	0.05.	For	all	statistical	
analyses,	SAS	System	version	9,	SAS	Institute,	Cary,	NC,	USA,	and	
SPSS	Statistics	version	23,	SPSS	Inc.,	Chicago,	IL,	USA,	were	used.
3  | RESULTS
3.1 | Patient enrollment and follow‐up
The	flowchart	of	the	study	is	shown	in	Figure	1.	A	total	of	49	patients	
were	included	in	the	study	and	randomized	into	two	study	groups:	
CXP	 (24	 patients,	 24	 implants)	 and	BG	 (25	 patients,	 25	 implants).	
The	baseline	patient	and	implant	site	characteristics	were	published	
previously	(Wessing	et	al.,	2017).	Two	patients	dropped	out	before	
TA B L E  1  Time	schedule	for	parameter	assessment
 
Pretreatment 
examination
Implant insertion 
and GBR procedure
1‐, 3‐, 6‐week 
and 3‐month 
follow‐up
Reentry 
surgery at 
6 months
Provisional 
prosthesis 
placement
Definitive 
prosthesis 
placement
1‐year 
follow‐up
Clinical	photographs X X X X X X X
Implant	survival    X X X X
Implant	success       X
Radiographic	
examinations
 X    X X
PES      X X
Bleeding	index       X
OHIP−14 X X X X X X X
Patient	satisfaction      X X
Adverse	Event	reporting  X X X X X X
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the	6-month	follow-up	due	to	moving	or	not	returning	for	the	next	
procedure.	 Forty-seven	 patients	 underwent	 the	 reentry	 surgery.	
Subsequently,	 five	 additional	 patients	were	 lost	 to	 follow-up	 (two	
did	 not	 return	 for	 definitive	 prosthesis	 delivery	 and	 three	 did	 not	
return	for	the	1-year	follow-up),	resulting	in	42	patients	(21	in	each	
group)	completing	the	1-year	visit.	Patient	and	implant	site	charac-
teristics	by	patients	available	versus	not	available	for	the	1-year	fol-
low-up	are	detailed	in	Table	2.
3.2 | Prosthetic delivery
Provisional	 prostheses	 were	 placed	 in	 28	 patients	 while	 the	 re-
maining	19	patients	directly	received	a	definitive	prosthesis	due	to	
economic	reasons.	Mean	definitive	prosthesis	delivery	time	was	at	
4.4	±	2.9	months	(CXP:	3.9	±	2.6	months;	range:	0.8–8.1	months;	BG:	
4.9	±	3.1	months;	range:	1.1–14.2	months)	after	the	reentry	surgery	
(6	months	after	GBR),	with	the	delays	due	to	patient	schedule,	soft	
tissue	 conditions,	 and	 economic	 reasons.	 Two	 patients	 had	 other	
treatments	(orthodontic	treatment	and	several	implants,	one	patient	
in	 each	 treatment	 group)	 and	 still	 had	 a	 provisional	 prosthesis	 at	
the	time	of	study	completion.	Overall,	20	patients	in	the	CXP	group	
and	 23	 patients	 in	 the	 BG	 group	 received	 definitive	 restorations.	
Procera	Esthetic	abutments	were	placed	in	26	patients	(12	CXP,	14	
BG),	Procera	Full	Contour	Zirconia	in	10	patients	(5	CXP,	5	BG),	and	
Esthetic	abutments	in	six	patients	(2	CXP,	4	BG);	for	one	abutment	
(CXP	 group),	 the	 information	 was	 not	 available.	 The	 restorations	
were	mainly	screw	retained	(34	patients).
3.3 | Outcome measures
The	 primary	 outcome	was	DH	 at	 6	months	 post-GBR,	 the	 results	
of	which	were	described	previously	 (Wessing	et	al.,	2017).	No	ad-
ditional	 DH	 analyses	 were	 performed	 in	 the	 current	 manuscript.	
Briefly,	 mean	 DH	 decreased	 from	 insertion	 to	 reentry	 6	 months	
later	from	5.1	±	2.1	mm	to	1.0	±	1.3	mm	in	the	CXP	group	and	from	
4.9	±	1.9	mm	to	1.7	±	2.1	mm	in	the	BG	group.	 In	the	CXP	group,	
mean	DH	reduced	by	81%	(n	=	23)	while	in	the	BG	group	mean	DH	
reduced	by	62%	(n = 24; p	=	0.14).
F I G U R E  1  CONSORT	2010	flowchart	of	the	study
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TA B L E  2  Patient	and	implant	site	characteristics	by	patients	who	completed	follow-up	and	who	were	lost	to	follow-up
Patient characteristics Completed follow‐up Lost to follow‐up
N 42 7
Gender
Female,	n	(%) 18	(43) 2	(29)
Male,	n	(%) 24	(57) 5	(71)
Age	at	surgery
Mean	±	SD	(years) 41.7 ± 17.6 43.9 ± 16.8
Smokinga
Non-smoking 34	(81) 4	(57)
Smoking	0–5	cigarettes/day,	n	(%) 3	(7) 0
Smoking	6–10	cigarettes/day,	n	(%) 5	(12) 5	(3)
History	of	periodontitis,	n	(%) 6	(14) 0
Treated	diabetes 1	(2) 0
Implant	site	characteristics
Position
Maxilla,	n	(%) 29	(69) 6	(86)
Mandible,	n	(%) 13	(31) 1	(14)
Type	of	site
Healed,	>6	months	post-extraction,	n	(%) 16	(38) 4	(57)
Healed,	>3	and	<	6	months	post-extraction,	n	(%) 21	(50) 3	(43)
Other	(agenesis) 5	(12) 0
Biotype   
Thin,	n	(%) 18	(43) 6	(86)
Thick,	n	(%) 24	(57) 1	(14)
Bone	quality
1,	n	(%) 4	(10) 0
2,	n	(%) 24	(57) 4	(57)
3,	n	(%) 14	(33) 3	(43)
4,	n	(%) 0 0
Bone	quantity
A,	n	(%) 8	(19) 0
B,	n	(%) 20	(48) 3	(43)
C,	n	(%) 11	(26) 3	(43)
D,	n	(%) 3	(7) 1	(14)
E,	n	(%) 0 0
Implant	insertion	torque
Mean	±	SD	(years) 42.9 ± 2.7 37.9 ± 8.4
Implant	position	in	the	bone
Subcrestal,	n	(%) 9	(21) 2	(29)
Equicrestal,	n	(%) 33	(79) 5	(71)
Defect	morphology
1	wall	missing,	n	(%) 36	(86) 7	(100)
2	walls	missing,	n	(%) 6	(14) 0
Membrane	fixation	method
Titanium	pins,	n	(%) 20	(48) 5	(71)
Sutures,	n	(%) 22	(52) 2	(29)
(Continues)
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At	1	year,	there	was	no	implant	failure	or	fracture,	and	all	surviv-
ing	 implants	were	successful,	 yielding	 the	1-year	CSR	and	success	
rate	of	100%.	No	device-related	adverse	events	were	reported	for	
either	group.
Overall,	 the	 MBLs	 remained	 stable	 from	 definitive	 prosthesis	
delivery	to	1-year	follow-up.	The	mean	MBL	was	−1.62	±	0.80	mm	
(n	=	40)	at	definitive	prosthesis	placement	and	−1.37	±	0.91	mm	(n	=	38)	
at	1	year.	 In	 the	CXP	group,	 the	mean	MBL	was	−1.37	±	0.77	mm	
(n	=	19)	and	−1.34	±	0.80	mm	(n	=	18)	at	definitive	prosthesis	place-
ment	and	at	1	year,	respectively.	In	the	BG	group,	the	mean	MBL	was	
−1.84	±	0.78	mm	(n	=	21)	and	−1.39	±	1.02	mm	(n	=	20)	at	definitive	
prosthesis	placement	and	at	1	year,	respectively.	The	differences	be-
tween	the	groups	were	not	statistically	significant.
The	mean	MBL	change	from	definitive	prosthesis	placement	to	1-
year	follow-up	was	+0.42	±	1.04	mm	(n	=	19)	for	BG,	+0.01	±	0.66	mm	
(n	=	18)	for	CXP,	and	+0.22	±	0.89	mm	(n	=	37)	overall.	The	difference	
between	the	groups	was	not	statistically	significant.	Marginal	bone	
level	changes	with	distribution	frequency	are	shown	in	Table	3.
Soft	 tissue	health	 improved	 from	definitive	prosthesis	delivery	
to	1-year	follow-up.	The	overall	PES	was	6.98	±	2.17	(n	=	43)	at	de-
finitive	prosthesis	delivery	and	increased	to	7.97	±	1.90	(n	=	39)	at	
1	year.	The	differences	between	the	two	groups	were	not	statisti-
cally	significant.	The	detailed	scores	of	all	seven	PES	variables	per	
group	and	a	sample	series	of	clinical	pictures	used	for	PES	evaluation	
are	shown	in	Table	4	and	Figure	2(a	and	b),	respectively.
The	 bleeding	 tendency	was	 evaluated	 at	 the	 1-year	 follow-up	
and	showed	no	bleeding	(mBI	index	0)	in	34	patients	(16	CXP	and	18	
BG)	and	isolated	spots	(mBI	index	1)	in	six	patients	(4	CXP	and	2	BG).
Patient	quality	of	life	evaluated	according	to	the	OHIP-14	ques-
tionnaire	 showed	 that	 overall	 patient	 discomfort	was	 6.5	 ±	 7.6	 at	
pretreatment	(CXP:	9.0	±	9.7,	n	=	20;	BG:	4.0	±	3.3,	n = 20; p	=	0.038),	
7.1	±	8.5	at	implant	insertion	(CXP:	9.0	±	10.6,	n	=	20;	BG:	5.3	±	5.4,	
n = 20; p	 =	 0.38),	 peaked	 at	 one	week	 post-surgery	with	 a	mean	
score	of	9.4	±	10.2	(CXP:	10.3	±	11.2,	n	=	20;	BG:	8.4	±	9.3,	n = 20; 
p	=	0.64),	and	from	then	on	continued	to	decrease	down	to	1.9	±	4.6	
at	the	1-year	follow-up	(CXP:	2.4	±	5.9,	n	=	20;	BG:	1.5	±	3.0,	n = 20; 
p	=	0.68),	with	no	statistical	significant	differences	between	the	two	
groups	 with	 the	 exception	 of	 the	 pretreatment	 assessment.	 The	
change	of	the	OHIP-14	scores	throughout	the	study	period	is	illus-
trated	in	Figure	3.
Mean	 functional	 and	 esthetic	 satisfaction	 scores	were	 >9.6	 at	
both	 definitive	 prosthesis	 delivery	 and	 1-year	 follow-up	 (Table	 5).	
No	 statistically	 significant	 differences	 were	 present	 between	 the	
two	groups.
4  | DISCUSSION
The	aim	of	this	randomized	controlled	trial	was	to	compare	the	clini-
cal	performance	of	a	novel	native	non-cross-linked	collagen	mem-
brane	with	a	reference	membrane	for	treatment	of	dehisced	implant	
sites	using	GBR.	As	previously	 reported,	 the	mean	 residual	DH	at	
the	time	of	reentry	procedure	in	the	current	study	was	1.3	±	1.7	mm	
for	both	groups,	1.7	±	2.1	mm	for	the	BG	group,	and	1.0	±	1.3	mm	
for	the	CXP	group	(Wessing	et	al.,	2017).	While	the	residual	height	
defect	in	the	BG	group	at	the	time	of	the	reentry	procedure	was	not	
in	the	range	of	residual	DH	required	by	Schwarz	et	al.	 (Schwarz	et	
al.,	2012),	the	CXP	group	was	inside	this	range.	Nevertheless,	it	does	
not	seem	to	be	possible	to	achieve	a	100%	defect	fill	with	implant	
placement	and	lateral	augmentation	with	resorbable	membranes	in	
a	 simultaneous	 approach.	 A	 systematic	 review	 and	 meta-analysis	
reported	 that	 only	75.4%	of	 the	 cases	 reached	 a	 complete	defect	
fill	(Jensen	&	Terheyden,	2009).	Findings	of	other	clinical	studies	in-
vestigating	GBR	with	 resorbable	membranes	 and	particulate	 graft	
materials	to	regenerate	dehiscence	defects	at	implant	sites	reported	
a	mean	defect	fill	of	61%–97%	(Carpio,	Loza,	Lynch,	&	Genco,	2000;	
Hammerle	 &	 Lang,	 2001;	 Nemcovsky,	 Artzi,	 Moses,	 &	 Gelernter,	
2000;	 Park	 et	 al.,	 2008;	 Tawil,	 El-Ghoule,	&	Mawla,	 2001).	 These	
data	are	in	agreement	with	the	findings	in	the	current	study,	with	a	
mean	defect	fill	of	71%.	Even	though	the	difference	between	both	
groups	was	not	statistically	significant,	 the	defect	 fill	 for	CXP	was	
noticeably	higher	with	a	mean	defect	fill	of	81%	versus	62%	for	BG.	
Patient characteristics Completed follow‐up Lost to follow‐up
Group	allocation
CXP,	n	(%) 21	(50) 3	(43)
BG,	n	(%) 21	(50) 4	(57)
Abbreviation:	SD,	standard	deviation.
aThe	status	of	one	patient	changed	based	on	monitoring	(the	patient	was	moved	from	a	light	smoker	to	a	heavy	smoker	group)	
TA B L E  2   (Continued)
TA B L E  3  Marginal	bone	level	changes
 
Definitive prosthesis to 1‐year follow‐up
All 
n = 37
CXP 
n = 37
CXP 
n = 19
Mean	±	SD	(mm) 0.22 ± 0.89 0.01 ± 0.66 0.42 ± 1.04
p-value	CXP	
versus	BG
 0.23  
Frequency N	(%) N	(%) N	(%)
>3.0	mm 1	(2.7) – 1	(5.3)
1.1	to	2.0	mm 5	(13.5) 1	(5.6) 4	(21.1)
0.1	to	1.0	mm 15	(40.5) 9	(50.0) 6	(31.6)
0 mm 1	(2.7) – 1	(5.3)
−1.0	to	−0.1	mm 14	(37.8) 7	(38.9) 7	(36.8)
−2.0	to	−1.1	mm 1	(2.7) 1	(5.6) –
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TA B L E  4  Pink	esthetic	score	at	definitive	prosthesis	delivery	and	at	1-year	follow-up	by	treatment	group
PES variable 
(mean ± SD)
CXP BG
Definitive prosthesis delivery 
(n = 20)
1‐year follow‐up 
(n = 20)
Definitive prosthesis delivery 
(n = 23)
1‐year follow‐up 
(n = 19)
Papilla	mesial 1.00	±	0.56 1.05	±	0.51 0.91 ± 0.67 1.32	±	0.58
Papilla	distal 1.00	±	0.65 0.95	±	0.76 0.70 ± 0.47 0.84	±	0.50
Soft	tissue	level 1.35	±	0.59 1.40 ± 0.68 1.17 ± 0.78 1.37 ± 0.60
Soft	tissue	Contour 1.00 ± 0.46 1.10	±	0.45 0.83 ± 0.49 0.89 ± 0.32
Alveolar	process 1.00	±	0.65 1.15	±	0.59 0.95	±	0.42 1.00 ± 0.47
Soft	tissue	color 1.00	±	0.56 1.10	±	0.55 0.78 ± 0.60 1.11 ± 0.32
Soft	tissue	texture 1.20	±	0.52 1.35	±	0.49 1.17 ± 0.49 1.32 ± 0.48
Overall	PES 7.55	±	2.06 8.10 ± 2.34 6.48 ± 2.17 7.84 ± 1.34
F I G U R E  2  Clinical	pictures	of	the	
restored	first	maxillary	premolar	(position	
24)	at	final	prosthesis	delivery	4	months	
after	the	reentry	procedure	(left)	and	at	
1-year	recall	(right)
(a) (b)
F I G U R E  3  Oral	health	impact	profile	
evaluated	with	OHIP-14	questionnaire	
per	group	(CXP:	18	patients;	BG:	17	
patients)	over	the	course	of	the	study	
period.	Scores	from	patients	who	had	not	
completed	the	questionnaire	at	any	of	
the	listed	timepoints	were	excluded.	The	
continuing	decrease	in	OHIP-14	score	
reflects	the	improving	quality	of	life
 
All 
n = 40
CXP 
n = 20
BG 
n = 20
p‐value CXP 
versus BG
Functional	satisfaction	
(mean	±	SD)
9.8 ± 0.4 9.8	±	0.5 9.8 ± 0.4 0.84
At	definitive	prosthesis	
delivery 
At	1	year
9.9 ± 0.3 9.9 ± 0.3 9.9 ± 0.3 0.27
Esthetic	satisfaction	
(mean	±	SD)
9.7 ± 0.7 9.7 ± 0.8 9.7 ± 0.7 0.84
At	definitive	prosthesis	
delivery 
At	1	year
9.7 ± 0.7 9.8	±	0.5 9.6 ± 0.9 0.54
TA B L E  5  Patient-reported	functional	
and	esthetic	satisfaction
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These	defect	fill	results	should	be	taken	into	account	when	compar-
ing	 the	marginal	bone	remodeling	between	the	6-month	 to	1-year	
follow-up	appointments.
In	this	manuscript,	we	evaluate	implant	survival	and	success	rate,	
changes	in	marginal	bone	level,	the	soft	tissue	conditions	around	the	
prosthetic	device,	and	quality	of	life	and	patient	satisfaction	at	pros-
thetic	delivery	and	1-year	recall.
Implant	 survival	 rate	 and	 the	 implant	 success	 rate	were	excel-
lent	in	both	groups	with	a	survival	rate	of	100%	and	a	success	rate	
of	 100%	 12	 months	 post-loading,	 which	 supports	 the	 use	 of	 the	
simultaneous	 approach	whenever	 possible	 as	 advocated	 in	 recent	
meta-analysis	(Wessing	et	al.,	2017).	The	success	rate	in	this	study	is	
very	high	in	comparison	with	another	recently	reported	randomized	
clinical	trial	with	a	similar	study	design	(Jonker,	Wolvius,	Tas,	&	Pijpe,	
2018)).	However,	in	that	study	the	authors	applied	a	more	rigid	set	of	
criteria	to	define	success	by	including	bone	loss	and	bleeding	index.
From	 definitive	 prosthesis	 placement	 to	 1-year	 follow-up,	 the	
BG	group	showed	marginal	bone	level	changes	of	+0.42	±	1.04	mm	
(n	 =	 19)	 and	 the	 CXP	 group	 had	 stable	 bone	 level	 changes	 with	
+0.01	±	0.66	mm	(n	=	18).	The	difference	was	not	statistically	signif-
icant	(p	=	0.230).	The	obtained	positive	values	suggest	subsequent	
bone	gain	but	have	to	be	viewed	critically.	All	X-rays	were	performed	
with	the	paralleling	technique,	which	gives	the	opportunity	to	choose	
another	angle	of	the	X-ray	tube	to	the	radiographic	film	and	might	
result	in	a	slightly	higher	bone	level	even	if	the	individualized	X-ray	
holder	is	held	at	the	same	position	at	every	timepoint.	The	accuracy	
and	reliability	of	such	radiographic	methods	show	an	overall	error	of	
0.11–0.5	mm	and	are	thus	in	the	observed	range	(Schulze	&	d'Hoedt,	
2001;	De	Smet,	Jacobs,	Gijbels,	&	Naert,	2002).	Nevertheless,	it	can	
be	concluded	that	the	mean	marginal	bone	loss	in	both	groups	is	less	
than	1.5	mm	after	12	months	of	 loading	 and	 therefore	 fulfills	 the	
requirements	for	implant	success.
Pink	esthetic	score	was	not	significantly	different	between	treat-
ment	groups	and	showed	generally	unsatisfactory	results	with	the	
mean	PES	7.55	±	2.06	at	prosthetic	delivery	and	8.10	±	2.34	at	1-year	
recall	in	the	CXP	group	versus	6.48	±	2.17	at	prosthetic	delivery	and	
7.84	±	1.34	at	1-year	recall	 in	the	BG	group.	These	mean	PES	val-
ues	were	comparable	to	those	in	some	studies	with	a	similar	surgical	
protocol:	8.1	±	1.2	reported	by	Buser	et	al.	(Buser	et	al.,	2009)	and	
7.8	reported	by	Jonker	et	al.	(Jonker	et	al.,	2018).	However,	in	other	
studies	PES	was	higher,	reaching	9.4	±	2.2	(Hof	et	al.,	2015)	and	even	
10.1	±	2.4	(Cosyn	et	al.,	2013).	The	unsatisfactory	scores	in	the	cur-
rent	study	were	observed	most	probably	due	to	the	augmentation	
procedure	and	the	extensive	mucoperiosteal	flap	raised	during	the	
reentry	procedure	performed	to	measure	bone	gain.	In	addition,	only	
one	patient	(in	the	BG	group)	received	soft	tissue	grafting	(Wessing	
et	al.,	2017).	Avoiding	an	extensive	mucoperiosteal	flap	during	the	
reentry	procedure	and	soft	tissue	grafting	are	both	likely	to	improve	
PES	values	and	should	be	investigated	in	future	studies.
Bleeding	indices	at	the	1-year	recall	appointment	were	excellent	
with	no	bleeding	in	85%	and	isolated	bleeding	spots	in	the	remain-
ing	patients,	representing	healthy	gingival	conditions	at	implant	sites	
(Farina,	Filippi,	Brazzioli,	Tomasi,	&	Trombelli,	2017).
OHIP-14	scores	continued	to	improve	from	1	week	after	GBR/
implant	placement,	with	the	final	mean	score	of	1.9	±	4.6	at	the	1-
year	recall	appointment,	which	reflects	a	strong	positive	impact	of	
the	 treatment	 on	 the	 patient	 quality	 of	 life.	 This	 result	 correlates	
with	 the	 subjective	patient-reported	esthetic	 and	 functional	 satis-
faction	of	9.8	±	0.5	for	the	CXP	group	and	9.8	±	0.4	for	the	BG	group	
at	prosthetic	delivery	and	9.9	±	0.3	for	the	CXP	group	and	9.9	±	0.3	
for	the	BG	group	at	1-year	recall.	These	patient-centered,	subjective	
outcome	values	are	very	high	in	comparison	with	other	recent	stud-
ies	(Jonker	et	al.,	2018;	Thoma	et	al.,	2016)	even	though	the	more	
objective	PES	values	were	relatively	low.
In	our	study,	the	simultaneous	implant	placement	and	GBR	were	
performed	as	a	closed	healing	procedure	using	mobilized	full-thick-
ness	flaps	to	achieve	tension-free	primary	wound	closure.	This	tech-
nique	 resulted	 in	 low	wound	dehiscence	 and	membrane	exposure	
rates	and,	consequently,	a	high	early	implant	survival	rate	of	100%	
at	reentry.	These	results	are	consistent	with	a	clinical	study	that	re-
ported,	after	5	years,	100%	implant	survival	rate	and	4.3	±	1.5	(SD)	
mm	buccal	vertical	bone	gain	between	implant	placement	and	5-year	
follow-up	for	patients	treated	with	a	resorbable	collagen	membrane	
(Jung,	Benic,	Scherrer,	&	Hammerle,	2015).
As	mentioned	in	the	previous	report	(Wessing	et	al.,	2017),	the	
primary	 limitation	 is	 that	 the	 study	was	 confined	 to	 investigating	
GBR	 of	 dehiscence	 defects	 alone.	 Additional	 studies	 are	 needed	
to	evaluate	the	effectiveness	of	this	membrane	for	more	extensive	
bone	augmentation	procedures,	such	as	sinus	lifts,	ridge	expansion,	
and	ridge	preservation.
The	 present	 study	was	 powered	 to	 test	 the	 non-inferiority	 of	
the	 CXP	 membrane	 against	 a	 competitor	 membrane.	 The	 study	
findings	thus	support	the	use	of	creos	xenoprotect	resorbable	col-
lagen	membrane	within	GBR	procedures	with	simultaneous	implant	
placement	at	dehisced	implant	sites.	Particular	results,	such	as	the	
low	membrane	exposure	rate,	look	promising	and	should	be	further	
investigated.	In	summary,	the	overall	findings	in	this	study	support	
the	need	for	further	testing	of	new	biomaterials	in	randomized	con-
trolled	clinical	studies	against	gold-standard	procedures	for	the	pa-
tient's	benefit.
5  | CONCLUSION
Both	collagen	membranes	in	this	multicenter	randomized	controlled	
trial	 resulted	 in	 safe	 bone	 augmentation	 of	 dehiscence	 defects	 at	
single	 implant	 sites	with	an	excellent	 implant	 survival	 and	 success	
rate	of	100%,	low	marginal	bone	loss,	low	bleeding	scores,	improved	
quality	of	life,	and	high	esthetic	and	functional	patient	satisfaction	
1	year	after	definitive	prosthesis	delivery.
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